APOLLOMICS INC Stock Price, News & Analysis

Apollomics (Nasdaq: APLM) announced board changes on November 16-17, 2025: Po-Jen Hsueh resigned from the board and his resignation was stated as not related to any disagreement with the company. The board appointed Dr. Ya-Chi (Claudia) Huang to fill the vacancy and named her to the Audit Committee and the Nominating and Corporate Governance Committee.

Following the change, the seven-member Board includes Hung-Wen (Howard) Chen (chair), Hong-Jung (Moses) Chen, Yi-Kuei Chen, Hsien-Shu Tsai, Yi-An Chu, Chen-Huan Jan, and Ya-Chi (Claudia) Huang, with five independent directors.

Dr. Huang’s background highlights biotechnology investment and R&D: she is Assistant Vice President at Maxpro Ventures (joined 2024), director at AngenMed Therapeutics, previously worked at Diamond Biofund (participated in Diamond’s 2023 Taiwan Stock Exchange IPO), and holds a Ph.D. in Microbiology from National Taiwan University.

Apollomics (Nasdaq: APLM) said Nasdaq notified the company on October 14, 2025 that the Listing Qualifications Staff determined Apollomics is in compliance with Nasdaq continued listing requirements.

As a result, Nasdaq cancelled the previously scheduled appeal hearing and Apollomics securities will remain listed and continue to trade on The Nasdaq Stock Market. The company had earlier filed an application to appeal a delisting notification and requested a hearing before a Nasdaq Hearings Panel.

Apollomics (Nasdaq: APLM) announced operational continuity after a leadership change and new funding, reversing prior wind-up plans.

The company said it received $4.1 million in PIPE funding on Sept 3, 2025, appointed a new board and management team, and intends to continue its global Phase 2 SPARTA program for APL-101 (vebreltinib), which has data from >280 patients. All CRO contracts are reported fully paid; the company has 12 employees and expects 15 by Oct 31, 2025. Apollomics also cites existing Chinese approvals for APL-101 in MET-amplified NSCLC and GBM via partners and intends to pursue broader regulatory filings.

Apollomics (NASDAQ: APLM) reported its full year 2024 financial results and clinical updates. The company secured a strategic collaboration with LaunXP for vebreltinib development, bringing in a $10 million upfront payment. Key clinical highlights include a 43% objective response rate in non-CNS MET fusion solid tumors and 30% response rate in high MET gene copy number patients.

Financial results show cash position of $9.8 million as of December 31, 2024, compared to $37.8 million in 2023. R&D expenses decreased to $24.6 million from $34.2 million, while administrative expenses reduced to $17.8 million from $20.6 million. Net loss for 2024 was $(53.9) million or $(52.80) per share, improved from $(172.6) million loss in 2023.

The company implemented strategic expense reductions and expects current cash, combined with the LaunXP payment, to fund operations into Q1 2026.

Apollomics (NASDAQ: APLM) has entered into a development and commercialization agreement with LaunXP for vebreltinib in combination with EGFR inhibitor for non-small cell lung cancer (NSCLC) treatment in Asia, excluding mainland China, Hong Kong, and Macau.

The deal includes $10 million in upfront payments to Apollomics within 60 days, potential pre-commercial milestones up to $50 million, and royalties on net product sales. LaunXP will lead the development of the combination therapy in their designated territory.

Vebreltinib, Apollomics' proprietary c-Met inhibitor, combined with EGFR inhibitor therapy aims to transform NSCLC treatment by potentially delaying resistance mutations and improving patient outcomes.

Apollomics (NASDAQ: APLM) announced disappointing top-line results from its Phase 3 bridging trial of uproleselan in China for relapsed or refractory acute myeloid leukemia patients. The trial, which enrolled 140 subjects randomized 1:1, failed to demonstrate favorable benefits when comparing uproleselan plus chemotherapy versus chemotherapy alone.

The median overall survival in the uproleselan arm was 9.3 months versus 14.3 months in the chemotherapy-only arm. While the drug was generally well-tolerated, serious adverse events occurred in 43% of uproleselan patients compared to 39% in the control group. Following these results and a previous failed global Phase 3 trial by partner Glycomimetics, Apollomics is concluding the program with expected remaining expenses under $500,000.

Apollomics (Nasdaq: APLM) has successfully regained compliance with Nasdaq's minimum bid price requirement. The company received confirmation on December 10, 2024, that its Class A Ordinary Shares maintained a closing bid price of $1.00 or higher for ten consecutive business days from November 25 to December 9, 2024. This development ensures the continued listing of Apollomics' shares on the Nasdaq Capital Market under the symbol 'APLM'. The matter is now considered closed.

Apollomics (Nasdaq: APLM) announced a 1-for-100 reverse share split of its class A ordinary shares, effective November 25, 2024. The split was approved by shareholders at the Extraordinary General Meeting on November 14, 2024. The company's shares will continue trading under 'APLM' with a new CUSIP number G0411D123. The authorized share capital will increase to 130,000,000 shares. As part of the split, warrant exercise prices will be adjusted, with public warrants' exercise price increasing to $1,150.00 from $11.50. No fractional shares will be issued.

Apollomics Inc. (Nasdaq: APLM) presented data on vebreltinib for non-small cell lung cancer (NSCLC) with METex14 skipping mutations at the ESMO Congress 2024. Key findings include:

1. Efficacy in both treatment-naïve and previously treated patients:
- Treatment-naïve: 66.7% overall response rate (ORR), 17.3 months median duration of response (DOR), 13.8 months median progression-free survival (PFS)
- Previously treated: 61.1% ORR, 16.7 months median DOR, 7.4 months median PFS

2. Efficacy regardless of MET gene copy number (GCN):
- GCN<4: 67.8% ORR
- GCN<6: 69.2% ORR
- GCN>4: 100% ORR (5/5 patients)

3. Safety profile: 48.1% of patients experienced grade 3 or higher treatment-related adverse events, with edema being most common (16.7%). No deaths were reported due to treatment-emergent adverse events.